Turoctocog alfa is an antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring...
- Mechanism
- Curator reviewed · 3 references
The B domain is known to perform the function of restrict the expression of the endogenous coagulation factor VIII but it has no direct relationship to the function of this factor. In normal conditions during hemostasis, the coagulation factor VIII will be activated by specific thrombin cleavages producing A1, A2 and A3-C1-C2 fragments of activated factor VIII (Factor VIIIa) which will form a complex with the factor IXa and activate the factor X leading to a stable haemostatic plug. Turoctocog contains all function-related domains with a considerably easier intact expression of the protein in mammalian cells by truncating the B domain. This recombinant structure allows it to replace the missing factor VIII and restore hemostasis.
- Primary indication
- Turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A.Curator reviewed · 2 structured indications
- Formula / weight
- C7480H11379N1999O2194S68 · 166000.0 Da (Without post-translational modifications)
- First approval
- Canada, 2014 · European Union, 2016
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Turoctocog alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account